Global Directory of Big Pharma Partnership Agreements 2021

DUBLIN, January 12, 2022 /PRNewswire/ — The “Global Big Pharma Partnership Terms and Agreements 2014-2021” report has been added to from offer.

The Global Big Pharma Partnering Terms and Agreements 2014-2021 report provides comprehensive access to available agreements and contractual documents for over 3,900 Big Pharma agreements.

These agreements tend to be multi-component, beginning with collaborative R&D and continuing through to the commercialization of the results.

The report presents the reader with a comprehensive review of Big Pharma deal trends, key players, major deal values, as well as deal financials, to understand how, why, and on what terms companies are entering into partnership agreements. with Big Pharma.

The report presents financial transaction terms values ​​for Big Pharma deals, listed by aggregate value, upfront payments, milestone payments, and royalties, allowing readers to analyze and compare the financial value of transactions.

The middle section of the report explores the key negotiators in the Big Pharma partnership arena; both the top trade values ​​and the most active Big Pharma trading companies are reported, allowing the reader to see who is succeeding in this dynamic trading market.

One of the main highlights of the report is that over 3,900 online records of actual Big Pharma transactions, as disclosed by the parties to the transaction, are included near the end of the report in a directory format – by company AZ, stage of development, transaction type, therapeutic focus and technology type – easy to view. Each transaction record in the report is linked via Weblink to an online version of the transaction.

In addition, when available, the records include contract documents as submitted to the Securities Exchange Commission by the companies and their partners. While many companies look for details on payment terms, the devil is in the details in terms of triggering payments – contract documents provide this information where press releases and databases do not.

The report also includes numerous tables and figures that illustrate the trends and activities of Big Pharma partnerships and deals since 2014.

In conclusion, this report provides everything a potential negotiator needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.

Report scope

Big Pharma partnership terms and agreements include:

  • Trends in Big Pharma deals in the biopharmaceutical industry since 2014
  • Access to master, initial, milestone and royalty data
  • Access to Big Pharma contract documents
  • Top Big Pharma deals by value since 2014
  • Most Active Big Pharma Traders Since 2014

In Global Big Pharma Partnering Terms and Agreements 2014-2021, available offers are listed by:

  • A-Z company
  • Face value
  • Stage of development at signing
  • Offer component type
  • Specific therapeutic target
  • Type of technology

The analysis of the actual contractual agreements makes it possible to evaluate the following elements:

  • What specific rights are granted or optional?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the transaction?
  • How are sales and payments audited?
  • What is the duration of the agreement?
  • How are the main terms of the agreement defined?
  • How are IPRs managed and owned?
  • Who is responsible for marketing?
  • Who is responsible for development, supply and manufacturing?
  • How are confidentiality and publication managed?
  • How to settle disputes?
  • Under what conditions can the agreement be terminated?
  • What happens if the owner changes?
  • What sub-licensing and sub-contracting arrangements have been agreed upon?
  • What boilerplate clauses does the company insist on?
  • What boilerplate clauses seem to differ from one partner to another or from one type of transaction to another?
  • What jurisdiction does the company insist on for contract law?

Main topics covered:


Chapter 1 Introduction

Chapter 2 – Trends in transactions with Big Pharma
2.1. introduction
2.2. Big Pharma partnership over the years
2.3. Most Active Big Pharma Traders
2.4. Big Pharma Partnership by Deal Type
2.5. Big Pharma Partnership by Therapeutic Area
2.6. Big Pharma partnership by type of technology
2.7. Terms of Agreement for Big Pharma Partnership
2.7.1 Key values ​​of the Big Pharma partnership
2.7.2 Upfront payments for Big Pharma transactions
2.7.3 Big Pharma Transaction Milestone Payments
2.7.4 Big Pharma Royalty Rates

Chapter 3 – Main agreements with large pharmaceutical companies
3.1. introduction
3.2. Best Big Pharma Deals by Value

Chapter 4 – Most Active Big Pharma Traders
4.1. introduction
4.2. Most Active Big Pharma Traders
4.3. Profiles of the most active Big Pharma partner companies
Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many more

Chapter 5 – Big Pharma Contract Trading Directory
5.1. introduction
5.2. Big Pharma Contract Trading Directory

Chapter 6 – Big Pharma Transactions by Type of Technology

Chapter 7 – Partner Resource Center
7.1. Online partnership
7.2. Partner events
7.3. Further Reading on Dealmaking

Appendix 1 – Big Pharma Transactions by AZ Company
Appendix 2 – Big Pharma transactions by stage of development
Appendix 3 – Big Pharma Transactions by Transaction Type
Annex 4 – Big Pharma offerings by therapeutic area
Annex 5 – Definitions of types of transactions

For more information on this report, visit

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets

Source link

Comments are closed.